Abstract
This practice parameter describes treatment with stimulant medication. It uses an evidence-based medicine approach derived from a detailed literature review and expert consultation. Stimulant medications in clinical use include methylphenidate, dextroamphetamine, mixed-salts amphetamine, and pemoline. It carries FDA indications for treatment of attention-deficit/hyperactivity disorder and narcolepsy.
Publication types
-
Guideline
-
Practice Guideline
-
Review
MeSH terms
-
Adolescent
-
Adult
-
Amphetamines / therapeutic use
-
Attention Deficit Disorder with Hyperactivity / drug therapy*
-
Brain / drug effects*
-
Central Nervous System Stimulants / adverse effects
-
Central Nervous System Stimulants / pharmacology
-
Central Nervous System Stimulants / therapeutic use*
-
Child
-
Child, Preschool
-
Contraindications
-
Drug Monitoring
-
Evidence-Based Medicine
-
Humans
-
Methylphenidate / therapeutic use
-
Narcolepsy / drug therapy
-
Pemoline / therapeutic use
-
Psychopharmacology
-
Psychotropic Drugs / therapeutic use*
-
United States
Substances
-
Amphetamines
-
Central Nervous System Stimulants
-
Psychotropic Drugs
-
Methylphenidate
-
Pemoline